Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$3.97 +0.08 (+2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$3.96 -0.01 (-0.13%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CMPX vs. DYN, BHC, SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, and STOK

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Dyne Therapeutics (DYN), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs. Its Competitors

Compass Therapeutics (NASDAQ:CMPX) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

In the previous week, Compass Therapeutics had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 4 mentions for Compass Therapeutics and 0 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.77 beat Compass Therapeutics' score of 0.43 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Compass Therapeutics Neutral
Dyne Therapeutics Very Positive

Compass Therapeutics currently has a consensus price target of $13.10, suggesting a potential upside of 229.97%. Dyne Therapeutics has a consensus price target of $34.07, suggesting a potential upside of 98.99%. Given Compass Therapeutics' higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Dyne Therapeutics
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
4 Strong Buy rating(s)
2.94

Compass Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass TherapeuticsN/AN/A-$49.38M-$0.45-8.82
Dyne TherapeuticsN/AN/A-$317.42M-$3.86-4.44

Compass Therapeutics' return on equity of -53.11% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -53.11% -46.14%
Dyne Therapeutics N/A -64.12%-56.75%

Summary

Compass Therapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$548.98M$3.42B$6.15B$10.77B
Dividend YieldN/A2.26%5.71%4.83%
P/E Ratio-8.8223.3129.7228.55
Price / SalesN/A271.94499.21189.70
Price / CashN/A45.1236.6160.67
Price / Book4.3610.4012.016.61
Net Income-$49.38M-$52.62M$3.32B$276.82M
7 Day Performance-6.81%2.14%1.54%1.96%
1 Month Performance13.75%10.90%6.10%2.53%
1 Year Performance125.57%13.64%61.10%32.80%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
2.4453 of 5 stars
$3.97
+2.1%
$13.10
+230.0%
+117.3%$548.98MN/A-8.8220Analyst Forecast
Gap Down
DYN
Dyne Therapeutics
3.0963 of 5 stars
$17.08
+4.3%
$34.07
+99.5%
-49.0%$2.33BN/A-4.42100Positive News
Analyst Forecast
Gap Up
BHC
Bausch Health Cos
4.6666 of 5 stars
$6.32
+4.5%
$9.00
+42.4%
-21.0%$2.24B$9.63B24.3220,700Positive News
Upcoming Earnings
Analyst Forecast
SRPT
Sarepta Therapeutics
4.5849 of 5 stars
$23.05
+2.4%
$34.42
+49.3%
-83.1%$2.20B$1.90B-26.491,372Analyst Forecast
ETNB
89BIO
2.8725 of 5 stars
$14.80
+0.3%
$25.81
+74.4%
+89.5%$2.19BN/A-4.1040Analyst Forecast
Short Interest ↓
MESO
Mesoblast
1.9919 of 5 stars
$17.65
+3.4%
$24.00
+36.0%
+82.5%$2.18B$17.20M0.0080
OCUL
Ocular Therapeutix
4.283 of 5 stars
$12.18
+2.9%
$22.63
+85.8%
+5.3%$2.06B$63.72M-9.52230
ANIP
ANI Pharmaceuticals
3.6948 of 5 stars
$95.12
+0.3%
$99.14
+4.2%
+60.7%$2.06B$614.38M-123.53600Analyst Upgrade
VERA
Vera Therapeutics
2.8921 of 5 stars
$30.20
-3.3%
$61.50
+103.6%
-29.3%$1.99BN/A-8.4440Analyst Forecast
COGT
Cogent Biosciences
2.3621 of 5 stars
$16.22
-1.0%
$19.67
+21.2%
+20.7%$1.87BN/A-9.1180Analyst Forecast
Gap Up
STOK
Stoke Therapeutics
3.1299 of 5 stars
$34.65
+3.3%
$30.83
-11.0%
+162.8%$1.84B$36.56M40.77100

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners